Goldman Sachs’s Intersect ENT, Inc XENT Stock Holding History

Goldman Sachs’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$1.4M	–	6952
2017 Q2	$1.4M	Buy	+50,000	New	+$1.13M	﹤0.01%	4146
2016 Q3	–	Sell	-200,000	Closed	-$2.59M	–	7252
2016 Q2	$2.59M	Buy	+200,000	New	+$3.13M	﹤0.01%	3397
2016 Q1	–	Sell	-50,000	Closed	-$1.13M	–	7400
2015 Q4	$1.13M	Buy	+50,000	New	+$989K	﹤0.01%	4182

Goldman Sachs's XENT Position: Q2 2022 in Review

Goldman Sachs sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 742,905 shares — an estimated $20.8M sold.

Goldman Sachs first reported a position in XENT in Q3 2014 and held it in 28 quarters. The position peaked at $20.8M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Goldman Sachs reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Goldman Sachs sold 742,905 Intersect ENT, Inc shares in Q2 2022, an estimated $20.8M.
Goldman Sachs first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 28 quarters.
Goldman Sachs's Intersect ENT, Inc position peaked at $20.8M in Q1 2022.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.